Not safe for consumption: Synthetic cannabinoids causing fatal acute rhabdomyolysis in two young men

Anthea B. Mahesan Paul, Lary Simms, Abraham Ebenezer Paul, Christopher Schmidseder, Andrew A. Mahesan, Jojo Yorke

ABSTRACT

Introduction: Synthetic cannabinoids are a class of recreational drugs that are included in the growing epidemic of synthetic recreational drugs sweeping the United States. Synthetic cannabinoids look, feel and act like Marijuana with dangerous and potentially fatal adverse effects. Synthetic cannabinoids, in addition are not detected by routine urine toxicology screening, and thus the magnitude of its prevalence is unknown.

Case Series: In this case series, we report two cases of fatal acute rhabdomyolysis associated with synthetic cannabinoid use in previously healthy young men. The strong correlation found by detailed history, clinical evaluation, and laboratory tests including the negative universal drug screen strongly suggests an association between synthetic cannabinoid use and fatal acute rhabdomyolysis in both cases.

Conclusion: Synthetic recreational drug use, including synthetic cannabinoids should be included in the differential diagnosis for acute rhabdomyolysis in young people with negative universal drug screens and initiatives should be taken to educate physicians and the general public of the serious consequences of synthetic cannabinoid use.
Not safe for consumption: Synthetic cannabinoids causing fatal acute rhabdomyolysis in two young men

Anthea B. Mahesan Paul, Lary Simms, Abraham Ebenezer Paul, Christopher Schmidseder, Andrew A. Mahesan, Jojo Yorke

ABSTRACT

Introduction: Synthetic cannabinoids are a class of recreational drugs that are included in the growing epidemic of synthetic recreational drugs sweeping the United States. Synthetic cannabinoids look, feel and act like Marijuana with dangerous and potentially fatal adverse effects. Synthetic cannabinoids, in addition are not detected by routine urine toxicology screening, and thus the magnitude of its prevalence is unknown. Case Series: In this case series, we report two cases of fatal acute rhabdomyolysis associated with synthetic cannabinoid use in previously healthy young men. The strong correlation found by detailed history, clinical evaluation, and laboratory tests including the negative universal drug screen strongly suggests an association between synthetic cannabinoid use and fatal acute rhabdomyolysis in both cases. Conclusion: Synthetic recreational drug use, including synthetic cannabinoids should be included in the differential diagnosis for acute rhabdomyolysis in young people with negative universal drug screens and initiatives should be taken to educate physicians and the general public of the serious consequences of synthetic cannabinoid use.

Keywords: Synthetic cannabinoids, Spice, Rhabdomyolysis

How to cite this article


Article ID: Z01201607CS10073AP
doi:10.5348/ijcri-201612-CS-10073

INTRODUCTION

Synthetic cannabinoids (SC) are a blend of herbal and chemical compounds used as a recreational drug that imitates the effects of marijuana. Synthetic cannabinoids have been sold in enticing packaging mislabeled as potpourri or herbal mixtures. The packages often labeled with, “not safe for consumption” have a variety of names including “Spice”, “K2”, “Nice Guy”, “NBT”, “Black Mamba” and “Crazy Monkey” [1]. Due to the relatively new advent of SCs, there is limited data available on the short-term and long-term effects of synthetic cannabinoid use. To our knowledge, this is the first case series of two fatalities that can be associated with acute rhabdomyolysis and synthetic cannabinoid use in the United States.
There have not been randomized controlled trials for SC use in the US and thus the documented effects of SCs are the result of subjective patient reporting. The commonly reported adverse effects of SC use by the CDC are drowsiness or lethargy (26.3%), emesis (16.4%), confusion (4.2%), tachycardia (29.0%), and agitation (35.3%) [2]. Spaderna et al. have summarized the less common adverse effects reported in the literature affecting a large range of organ systems including neurological, cardiovascular, psychological, and gastrointestinal adverse effects [3].

Physicians and healthcare personnel should be aware of the possibility of potentially fatal rhabdomyolysis in patients that use synthetic cannabinoids.

CASE SERIES

Case 1

A 30-year-old Caucasian male presented to the emergency room unconscious and unresponsive after being on an 8-day synthetic cannabinoid binge (NBT brand). According to his fiancé, he experienced nausea and vomiting for approximately six days before hospital admission accompanied by abdominal pain and difficulty urinating. His urine was described as dark brown. In addition he complained of muscle cramps, and soreness. The patient had a history of spice use for the past two years, and was a ½ pack a day smoker. He had no history of other drug use, or any relevant medical or surgical history. On admission, He exhibited hypertension, oliguria, muscle tenderness accompanied with creatinine phosphokinase levels of 47,000 IU, hyperkalemia, BUN: 51 mg/dL, abnormal liver function tests, creatinine: 5.15 mg/dL, hypocalcaemia and hypoalbuminemia consistent with severe rhabdomyolysis. Universal drug screen was negative. Despite aggressive intravenous hydration, forced diuresis, and hemodialysis, the oliguria persisted and the patient died 5 days after admission with renal failure and ventilator associated bilateral pneumonia. (Figure 1)

Case 2

A 23-year-old African-American male with history of substance abuse, and no other significant past medical history, presented to the emergency room complaining of nausea, vomiting, chest pain, generalized weakness, generalized body aches and muscle cramps that began approximately four days before admission. He had a history of exclusive spice use for the past five days. He also complained of sharp retrosternal chest pain, muscle pain being unable to walk for three days prior, accompanied with low urine output. The patient was a former occasional smoker and occasional alcoholic, last use of both cigarettes and alcohol was 1 week prior. On admission, the patient was hypertensive with a blood pressure of 170/82 mmHg. Laboratory findings showed abnormal findings consistent with dehydration and rhabdomyolysis with creatine kinase level of 37,200 IU, CK-MB: 113.7 ng/mL, abnormal liver function tests, hyponatremia with sodium of 105 mmol/L, creatinine: 4.26 mg/dL, hypocalcaemia, hyperkalemia, BUN: 120 mg/dL, and elevated Troponins. Universal drug screen was negative. Despite aggressive intravenous hydration, forced diuresis, hemodialysis, and supplementation the patient rapidly deteriorated and died three days after admission. (Figure 2) (Table 1).

Table 1: Laboratory Values for Patient 1 and Patient 2 on Admission

<table>
<thead>
<tr>
<th>Test</th>
<th>Patient 1</th>
<th>Normal Values</th>
<th>Patient 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPK</td>
<td>47,000</td>
<td>H (52-336) U/L</td>
<td>37,200</td>
</tr>
<tr>
<td>Potassium</td>
<td>2.5</td>
<td>H (3.5-5.5) mmol/L</td>
<td>4.9 *</td>
</tr>
<tr>
<td>BUN</td>
<td>51</td>
<td>H (7-18) mg/dL</td>
<td>120</td>
</tr>
<tr>
<td>SGOT/AST</td>
<td>1044</td>
<td>H (15-37)</td>
<td>5053</td>
</tr>
<tr>
<td>SGPT/ALT</td>
<td>241</td>
<td>H (12-78)</td>
<td>2228</td>
</tr>
<tr>
<td>Creatinine</td>
<td>5.15</td>
<td>H (0.52-1.23) mg/dL</td>
<td>5.69 H</td>
</tr>
<tr>
<td>Calcium</td>
<td>6</td>
<td>L (8.5-10.1) mg/dL</td>
<td>5.2 L</td>
</tr>
<tr>
<td>Albumin</td>
<td>3.2</td>
<td>L (3.4-5.0) g/dL</td>
<td>3</td>
</tr>
<tr>
<td>Sodium</td>
<td>121</td>
<td>L (136-145) mmol/L</td>
<td>105 L</td>
</tr>
<tr>
<td>Estimated GFR</td>
<td>18</td>
<td>L mL/min</td>
<td>10</td>
</tr>
<tr>
<td>Drug screen</td>
<td>Negative</td>
<td>*</td>
<td>Negative</td>
</tr>
</tbody>
</table>

Abbreviations: H= High, L= Low, *= Normal
DIscUssion

Unfortunately, young people are being victimized by the recreational synthetic drug epidemic sweeping the United States. Though the exact number of regular SC users is undetermined, according to a study at American high schools, 11% of 12th graders and 4% of 8th graders reported using SC products in the year 2013 [4]. In addition, the CDC reported a stark increase of calls regarding effects from SC use by 229% in 2015 from the same January–May period in 2014 [2]. Although it is apparent the prevalence of SC use is on the rise, Buser et al. found that young adults and adolescents appear to be unaware of the health risks associated with synthetic cannabinoids [5].

Since its debut in the United States in 2009, legislature has struggled to keep up with the growing epidemic of synthetic recreational drug use. In the summer of 2012, President Obama signed legislation to include 21 different synthetic cannabinoid compounds and five overall cannabinoid structural classes into Schedule I of the Controlled Substances Act (CSA) [6]. The legislature worldwide struggles to keep up with the synthetic manufacturing of these recreational drugs with the total number of identified SC compounds reaching over 84 as of May 2013 [7].

The major users of SCs have been suggested to be populations wishing to avoid drug detection such as parolees, students and military staff due to the inability of the drug to be detected through the standard urine drug screening [8]. Another hypothesis has been proposed that SCs may be used as an adulterant to unsuspecting consumers under the guise of marijuana, due to the relatively low price of about $6-10 USD per gram [9]. Regardless of the intentional or unintentional consumption of this drug, the dilemma remains that the general public remains ignorant of the dangerous and potentially fatal adverse effects of SC use.

A limitation of this case series is the inability to chemically confirm the presence of SCs at the time of admission. This association between SC use and acute fatal rhabdomyolysis was made after careful exclusion of other potential causes aided by a detailed history attained from the patients and patients’ families, clinical evaluation, and laboratory tests including the negative universal drug screen. Through the universal drug screen it is apparent that our patients were not abusing other drugs at the time of admission and this supports our hypothesis that the history of SC use was the key contributing factor to the development of acute rhabdomyolysis.

A number of recreational drugs commonly abused including benzodiazepines, ecstasy, heroin, ketamine hydrochloride, marijuana, lysergic acid diethylamide, methamphetamine, narcotics, phencyclidine, ethanol and cocaine have been associated with drug-induced acute rhabdomyolysis [10]. It is suggested that acute rhabdomyolysis could occur from muscle destruction by compression and ischemia due to muscular hyperactivity, extreme exercise, and catatonic states brought on by acute recreational drug intoxication [11].

COncLUsION

With the legalization of medical marijuana in 23 states in the US it is easy to see how synthetic cannabinoids that feel, smell and look the same may be misleading to some individuals. Initiatives should be under taken to educate
physicians and the general public of the consequences and effects of SC use and synthetic recreational drugs as a whole.

Acknowledgements
We would like to thank the Clark County Coroner’s Office, Las Vegas, Nevada and Dr. Gurumurthy of CHARCOS, Spartan Health Sciences University for the ongoing support. Portions of this case report have been presented in abstract form at the American College of Physicians Annual Fall Scientific Meeting: Nevada Chapter; Las Vegas, NV on December 4, 2015.

Author Contributions
Anthea B. Mahesan Paul – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Lary Simms – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Abraham Ebenezer Paul – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Andrew A. Mahesan – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Christopher Schmidseder – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Jojo Yorke – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published

Guarantor
The corresponding author is the guarantor of submission.

Conflict of Interest
Authors declare no conflict of interest.

Copyright
© 2016 Anthea B. Mahesan Paul et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided

the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.

REFERENCES

SUGGESTED READING
Edorium Journals: An introduction

Edorium Journals Team

About Edorium Journals

Edorium Journals is a publisher of high-quality, open access, international scholarly journals covering subjects in basic sciences and clinical specialties and subspecialties.

Invitation for article submission

We sincerely invite you to submit your valuable research for publication to Edorium Journals.

But why should you publish with Edorium Journals?

In less than 10 words - we give you what no one does.

Vision of being the best

We have the vision of making our journals the best and the most authoritative journals in their respective specialties. We are working towards this goal every day of every week of every month of every year.

Exceptional services

We care for you, your work and your time. Our efficient, personalized and courteous services are a testimony to this.

Editorial Review

All manuscripts submitted to Edorium Journals undergo pre-processing review, first editorial review, peer review, second editorial review and finally third editorial review.

Peer Review

All manuscripts submitted to Edorium Journals undergo anonymous, double-blind, external peer review.

Early View version

Early View version of your manuscript will be published in the journal within 72 hours of final acceptance.

Manuscript status

From submission to publication of your article you will get regular updates (minimum six times) about status of your manuscripts directly in your email.

Our Commitment

Six weeks

You will get first decision on your manuscript within six weeks (42 days) of submission. If we fail to honor this by even one day, we will publish your manuscript free of charge.*

Four weeks

After we receive page proofs, your manuscript will be published in the journal within four weeks (31 days). If we fail to honor this by even one day, we will publish your manuscript free of charge and refund you the full article publication charges you paid for your manuscript.*

Favored Author program

One email is all it takes to become our favored author. You will not only get fee waivers but also get information and insights about scholarly publishing.

Institutional Membership program

Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in fees make their research accessible to all.

Our presence

We have some of the best designed publication formats. Our websites are very user friendly and enable you to do your work very easily with no hassle.

Something more...

We request you to have a look at our website to know more about us and our services.

* Terms and condition apply. Please see Edorium Journals website for more information.

We welcome you to interact with us, share with us, join us and of course publish with us.

Edorium Journals: On Web

Browse Journals

CONNECT WITH US

This page is not a part of the published article. This page is an introduction to Edorium Journals and the publication services.